US Edition'Buy' Sun Pharma Shares Maintains Nirmal Bang, Says India, Specialty To Drive Growth
Summary by NDTV Profit
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
'Buy' Sun Pharma Shares Maintains Nirmal Bang, Says India, Specialty To Drive Growth
While near-term headwinds such as elevated marketing expenses, rising tax rates, and persistent pricing pressure in the U.S. generics business have led the brokerage to tweak its estimates, thus remains constructive on Sun Pharma’s long-term fundamentals. NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
